GlassScriptPhysician profile
Charles R Moore
NPI 1801058821
$5,825.98
in general payments reported to CMS, 2019-2025
47 companies · $685 in 2025
The $685 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,087 · 2020: $581 · 2021: $928 · 2022: $722 · 2023: $889 · 2024: $934 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,507.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $739.82 | 2019-2025 | Xtandi |
| Allergan, INC. | $666.44 | 2019-2022 | |
| Janssen Biotech, INC. | $633.60 | 2019-2025 | Erleada |
| Abbvie INC. | $530.37 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $495.43 | 2023-2025 | Gemtesa, Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $481.66 | 2019-2025 | |
| Pfizer INC. | $454.26 | 2019-2025 | |
| Coloplast Corp | $340.32 | 2019-2025 | Titan |
| Ethicon US, LLC | $178.43 | 2019-2024 | Harmonic, Echelon Flex, Certus 140 |
| Urogen Pharma, INC. | $110.95 | 2021-2025 | Jelmyto |
| Tolmar Pharmaceuticals, INC. | $103.42 | 2019-2022 | |
| Urovant Sciences INC | $77.69 | 2021-2022 | |
| Braemar Manufacturing, LLC | $72.77 | 2019 | |
| Mission Pharmacal Company | $68.25 | 2021-2024 | Uribel Tabs, Uribel |
| Tela Bio, INC. | $67.42 | 2024-2025 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.